HOLD with tightened risk controls (stops at $1,140, protective puts at $1,130 strike for 60 days if position exceeds 5% of portfolio); reject accumulation at $1,144-$1,160; wait for confirmation above $1,185 or pullback to $1,050-$1,090

• Forward P/E of 25.6x depends on $45.06 EPS materializing; Q2 miss could expand multiple to 30x+
• 50 SMA at $1,144 has only $10 buffer (~1%) from $1,154.97 close; entering earnings with momentum turning over
• MACD crossed bearish with expanding negative histogram; 10 EMA lost on 50% above-average volume
• High-volume distribution candle closed near session low after gap down from $1,210 prior close
• Stop at $1,136 from $1,155 entry = $19 risk (~1.6%); 200 SMA at $1,021 represents potential 12% additional drawdown
• Beta of 0.506 is backward-looking; single-session drop of 4.55% shows company-specific risk not captured by beta
• Amgen's MariTide running six Phase 3 trials (not one shot); Novo oral GLP-1 launching now; LLY's orforglipron has active regulatory timelines
• Resilience deal at $750M could indicate supply concerns or overbuilding into softening demand
• Atai/Beckley acquisition at $2.8B at peak of psychedelic hype cycle represents poor expected capital allocation
• Inventory up 56% YoY matching revenue growth of 55.5% could signal channel pre-positioning or early demand softening
• Low consensus bar ($45 EPS) does not create buying opportunity at premium multiple; miss could trigger 10-15% re-rating
• Competitive catalyst or regulatory event can drive 15-20% drawdown regardless of market beta

→ vs aggressive: Revenue growth of 55.5%, operating margins of 49.4%, and ROE of 107.5% are celebrated without acknowledging that 25.6x forward P/E depends entirely on $45.06 EPS materializing—any Q2 disappointment compresses earnings base and expands the multiple to 30x+

→ vs aggressive: Technical 'test not breakdown' framing ignores that close near session low after gap-down on high volume is a distribution candle, not a reversal shakeout; 50 SMA buffer of less than 1% entering earnings in 1-2 weeks is insufficient protection

→ vs aggressive: Accumulation between $1,144-$1,160 with stop at $1,136 assumes stop holds, but stops at support levels with momentum turning routinely trigger on noise—$750M Resilience deal signals management concern about supply constraints or overbuilding risk—$2.8B Atai/Beckley acquisition made at psychedelic hype peak has poor expected return

HOLD

• Fundamentals support holding - 55.5% revenue growth, 49% operating margins, 107% ROE are generational compounder metrics
• Forward P/E of 25.6x depends on $45 forward EPS materializing - consensus not guaranteed
• Technical: $1,154.97 closed above $1,144.77 (50 SMA) but buffer is less than 1% and less than one-third of ATR - hair's breadth, not comfortable margin
• Candle structure showing distribution signature: closing near session low on 50% above-average volume after gap down
• $1,136 stop is correct and coincides with Bollinger Lower Band at $1,136.37 - technical confluence level
• $1,140 stop rejected - would exit before actual breakdown confirms (50 SMA would already be broken)
• Amgen MariTide is a slow-burn overhang justifying neutral weight but not an exit - single Phase 3 readout or leaked data can compress multiple
• AtaiBeckley acquisition ($2.8B) is less than two quarters of free cash flow and logical for pipeline diversification - watch item, not thesis-breaker
• Inventory build interpretation ambiguous - Q2 earnings will resolve whether proactive preparation or demand softening
• Earnings setup is concerning: low bar doesn't mean bullish at 25x forward P/E; premium-multiple stocks need beat, not just meet
• Beta of 0.506 measures market correlation, not company-specific drawdown; LLY dropped 4.55% in single session
• Aggressive accumulation proposal rejected: buying between $1,144-$1,160 is falling knife into momentum breakdown
• Conservative's $1,140 stop tightening rejected: would result in whipsawing on noise before signal
• Recommended framework: neutral position sizing, $1,136 stop, $1,185 re-entry with volume confirmation, $1,050-$1,090 post-Q2 add zone if thesis confirmed
• Partial hedges only warranted if position exceeds 5% of portfolio - evaluate cost-benefit rather than automatic application

→ vs aggressive: Fundamentals case is valid but accumulation thesis flawed - buying a falling knife into a momentum breakdown with a flagged lukewarm earnings event is directional, not asymmetric

→ vs conservative: $1,136 stop already coincides with Bollinger Lower Band - tightening to $1,140 would exit before breakdown confirms, selling on noise rather than signal and potentially getting whipsawed out only to watch the stock rally